Every year, tens of thousands of people who fall ill with tuberculosis in South Africa are not diagnosed. Because of this, there has been much focus on testing people earlier rather than waiting for them to show up at clinics when they are already sick. One potential solution, explored in a trial called XACT 2, is community-based testing using a point-of-care molecular test. Tiyese Jeranji spoke to experts involved with XACT 2 and unpacks the study’s findings that were recently published in Nature Medicine.
Roughly two in five people newly ill with TB worldwide are never diagnosed. In South Africa, this amounts to about 120 000 to 160 000 people per year. A large new study called XACT III is testing ways in which more people can be diagnosed and started on TB treatment more quickly. Tiyese Jeranji reports.